Indications of Persistent Glycocalyx Damage in Convalescent COVID-19 Patients: A Prospective Multicenter Study and Hypothesis

被引:28
|
作者
Vollenberg, Richard [1 ]
Tepasse, Phil-Robin [1 ]
Ochs, Kevin [1 ]
Floer, Martin [2 ]
Strauss, Markus [3 ]
Rennebaum, Florian [1 ]
Kabar, Iyad [1 ]
Rovas, Alexandros [4 ]
Nowacki, Tobias [1 ,5 ]
机构
[1] Univ Hosp Muenster, Dept Med B Gastroenterol Hepatol Endocrinol & Cli, D-48149 Munster, Germany
[2] Klinikum Ibbenburen, Dept Med 1, D-49477 Ibbenburen, Germany
[3] Univ Hosp Muenster, Dept Cardiol Coronary I Peripheral Vasc Dis Heart, D-48149 Munster, Germany
[4] Univ Hosp Muenster, Dept Med D, Div Gen Internal & Emergency Med Nephrol & Rheuma, D-48149 Munster, Germany
[5] Marienhosp Steinfurt, Dept Med Gastroenterol, D-48565 Steinfurt, Germany
来源
VIRUSES-BASEL | 2021年 / 13卷 / 11期
关键词
SARS-CoV-2; COVID-19; syndecan-1; glycocalyx; long-COVID-19; INFECTION;
D O I
10.3390/v13112324
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The COVID-19 pandemic is caused by the SARS CoV-2 virus and can lead to severe lung damage and hyperinflammation. In the context of COVID-19 infection, inflammation-induced degradation of the glycocalyx layer in endothelial cells has been demonstrated. Syndecan-1 (SDC-1) is an established parameter for measuring glycocalyx injury. This prospective, multicenter, observational, cross-sectional study analyzed SDC-1 levels in 24 convalescent patients that had been infected with SARS-CoV-2 with mild disease course without need of hospitalization. We included 13 age-matched healthy individuals and 10 age-matched hospitalized COVID-19 patients with acute mild disease course as controls. In convalescent COVID-19 patients, significantly elevated SDC-1 levels were detected after a median of 88 days after symptom onset compared to healthy controls, whereas no difference was found when compared to SDC-1 levels of hospitalized patients undergoing acute disease. This study is the first to demonstrate signs of endothelial damage in non-pre-diseased, convalescent COVID-19 patients after mild disease progression without hospitalization. The data are consistent with studies showing evidence of persistent endothelial damage after severe or critical disease progression. Further work to investigate endothelial damage in convalescent COVID-19 patients should follow.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study
    Abolghasemi, Hassan
    Eshghi, Peyman
    Cheraghali, Abdol Majid
    Fooladi, Abbas Ali Imani
    Moghaddam, Farzaneh Bolouki
    Imanizadeh, Sina
    Maleki, Matin Moeini
    Ranjkesh, Mohammad
    Rezapour, Mohammad
    Bahramifar, Ali
    Einollahi, Behzad
    Hosseini, Mohammad Javad
    Jafari, Nematollah Joneidi
    Nikpouraghdam, Mohamad
    Sadri, Nariman
    Tazik, Mokhtar
    Sali, Shanaz
    Okati, Shamsi
    Askari, Elham
    Tabarsi, Payam
    Aslani, Jafar
    Sharifipour, Ehsan
    Jarahzadeh, Mohammad Hossein
    Khodakarim, Nastaran
    Salesi, Mahmood
    Jafari, Ramezan
    Shahverdi, Samira
    TRANSFUSION AND APHERESIS SCIENCE, 2020, 59 (05)
  • [32] Long-Term Outcomes of COVID-19 and Risk Factors for Prolonged or Persistent COVID-19 in Lymphoma Patients: A Multicenter, Retrospective Cohort Study
    Lee, Jung Ah
    Han, Min
    Ahn, Sangmin
    Lee, Yongseop
    Yeom, Joon-Sup
    Choi, Jun Yong
    Ku, Nam Su
    Jeong, Su Jin
    Kim, Jung Ho
    Kim, Jin Seok
    Chung, Haerim
    Cho, Hyunsoo
    Kim, Yu Ri
    Ahn, Jin Young
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2024, 39 (41)
  • [33] Clinical and immunological characteristics in COVID-19 convalescent patients
    Zhiying Su
    Wenjia Hu
    Qianyun Liu
    Yongxi Zhang
    Tielong Chen
    Yingying Zhou
    Zhen Zhang
    Yu Chen
    Rongrong Yang
    Yong Xiong
    Xinghuan Wang
    European Journal of Clinical Microbiology & Infectious Diseases, 2021, 40 : 2669 - 2676
  • [34] Sustained prothrombotic changes in convalescent patients with COVID-19
    Meijenfeldt, Fien A. von
    Thalin, Charlotte
    Lisman, Ton
    LANCET HAEMATOLOGY, 2021, 8 (07): : E475 - E475
  • [35] Treatment of immunocompromised COVID-19 patients with convalescent plasma
    Fung, Monica
    Nambiar, Ashok
    Pandey, Suchi
    Aldrich, J. Matthew
    Teraoka, Justin
    Freise, Christopher
    Roberts, John
    Chandran, Sindhu
    Hays, Steven R.
    Bainbridge, Emma
    DeVoe, Catherine
    Roque Gardner, Annelys
    Yokoe, Deborah
    Henrich, Timothy J.
    Babik, Jennifer M.
    Chin-Hong, Peter
    TRANSPLANT INFECTIOUS DISEASE, 2021, 23 (02)
  • [36] Effectiveness of convalescent plasma in Indian patients with COVID-19
    Budhiraja, Sandeep
    Dewan, Arun
    Aggarwal, Ritesh
    Singh, Omender
    Juneja, Deven
    Pathak, Sangeeta
    Singh, Y. P.
    Gupta, Ajay
    Rai, Reeta
    Indrayan, Abhaya
    Jha, Vinitaa
    Naithani, Rahul
    BLOOD CELLS MOLECULES AND DISEASES, 2021, 88
  • [37] Use of convalescent plasma in COVID-19 patients with immunosuppression
    Senefeld, Jonathon W.
    Klassen, Stephen A.
    Ford, Shane K.
    Senese, Katherine A.
    Wiggins, Chad C.
    Bostrom, Bruce C.
    Thompson, Michael A.
    Baker, Sarah E.
    Nicholson, Wayne T.
    Johnson, Patrick W.
    Carter, Rickey E.
    Henderson, Jeffrey P.
    Hartman, William R.
    Pirofski, Liise-anne
    Wright, R. Scott
    Fairweather, De Lisa
    Bruno, Katelyn A.
    Paneth, Nigel S.
    Casadevall, Arturo
    Joyner, Michael J.
    TRANSFUSION, 2021, 61 (08) : 2503 - 2511
  • [38] Clinical and immunological characteristics in COVID-19 convalescent patients
    Su, Zhiying
    Hu, Wenjia
    Liu, Qianyun
    Zhang, Yongxi
    Chen, Tielong
    Zhou, Yingying
    Zhang, Zhen
    Chen, Yu
    Yang, Rongrong
    Xiong, Yong
    Wang, Xinghuan
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2021, 40 (12) : 2669 - 2676
  • [39] Is convalescent plasma an alternative treatment for Covid-19 patients?
    Enrique Trejo-Gomora, Jorge
    Dimas-Gonzalez, Jisela
    Lagunas-Martinez, Alfredo
    SALUD PUBLICA DE MEXICO, 2020, 62 (06): : 870 - 871
  • [40] Therapeutic use of convalescent plasma in patients with COVID-19
    Prieto Jimenez, Leobaldo
    Diaz Diaz, Daniel
    Gonzalez Betancourt, Annalia
    Fernandez Aguila, Julio D.
    MEDISUR-REVISTA DE CIENCIAS MEDICAS DE CIENFUEGOS, 2020, 18 (05): : 1015 - 1022